Cover Image
市場調查報告書

乾燥症(修格蘭氏症候群):開發平台分析

Sjogren's Syndrome - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 200491
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
乾燥症(修格蘭氏症候群):開發平台分析 Sjogren's Syndrome - Pipeline Review, H1 2015
出版日期: 2015年05月20日 內容資訊: 英文 63 Pages
簡介

所謂乾燥症(修格蘭氏症候群)是自體免疫疾病,會引起各系統及組織發炎。症狀有皮疹和皮膚乾燥、陰道乾燥、持續性乾咳、長期疲勞感、乾眼症、口乾、關節痛、腫和僵硬等。致病因素有年齡及性別、風濕性疾病等。

本報告提供乾燥症(修格蘭氏症候群)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

乾燥症(修格蘭氏症候群) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • MedImmune, LLC
  • Novartis AG
  • 武田藥品工業
  • Toleranzia AB

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abatacept (recombinant)
  • ABS-11
  • Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome
  • CFZ-533
  • IMSO-001
  • MEDI-4920
  • MLN-3126
  • NS2
  • Recombinant Protein for Sjogren's Syndrome
  • Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders
  • VAY-736

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6744IDB

Summary

Global Markets Direct's, ‘Sjogren's Syndrome - Pipeline Review, H1 2015', provides an overview of the Sjogren's Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sjogren's Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sjogren's Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sjogren's Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Sjogren's Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Sjogren's Syndrome - Overview
    • Pipeline Products for Sjogren's Syndrome - Comparative Analysis
  • Sjogren's Syndrome - Therapeutics under Development by Companies
  • Sjogren's Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Sjogren's Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Sjogren's Syndrome - Products under Development by Companies
  • Sjogren's Syndrome - Products under Investigation by Universities/Institutes
  • Sjogren's Syndrome - Companies Involved in Therapeutics Development
    • Aegera Therapeutics Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • MedImmune, LLC
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Toleranzia AB
  • Sjogren's Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABS-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMG-557 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CFZ-533 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Coversin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMSO-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MEDI-4920 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLN-3126 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Sjogren's Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAY-736 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sjogren's Syndrome - Recent Pipeline Updates
  • Sjogren's Syndrome - Dormant Projects
  • Sjogren's Syndrome - Discontinued Products
  • Sjogren's Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Mar 24, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial
      • Mar 17, 2015: Aldeyra Therapeutics Opens Enrollment in Sjogren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol
      • Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program
      • Jan 29, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting
      • Jan 26, 2015: Aldeyra Therapeutics to Participate in Canaccord Genuity Rare Disease, BioPharma One-on-One Day
      • Jan 05, 2015: Aldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients With Sjogren-Larsson Syndrome
      • Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting
      • Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sjogren's Syndrome, H1 2015
  • Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Investigation by Universities/Institutes, H1 2015
  • Sjogren's Syndrome - Pipeline by Aegera Therapeutics Inc., H1 2015
  • Sjogren's Syndrome - Pipeline by Amgen Inc., H1 2015
  • Sjogren's Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2015
  • Sjogren's Syndrome - Pipeline by MedImmune, LLC, H1 2015
  • Sjogren's Syndrome - Pipeline by Novartis AG, H1 2015
  • Sjogren's Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
  • Sjogren's Syndrome - Pipeline by Toleranzia AB, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Sjogren's Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
  • Sjogren's Syndrome - Dormant Projects, H1 2015
  • Sjogren's Syndrome - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Sjogren's Syndrome, H1 2015
  • Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top